Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + Cemiplimab in peri-operative CSCC
NCT06384820Phase 2Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of fianlimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Regeneron Pharmaceuticals. Planned start Nov 2024; status: withdrawn.
02
Drugs
fianlimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06384820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384820.